Phase i prospective trial of tas-102 (trifluridine and tipiracil) and radioembolization with

HIGHLIGHTS

• who: Nicholas Fidelman from the This was a phase I dose escalation study (, + , design) with a dose expansion arm (, patients) designed to evaluate safety of the combination of , and TARE using Y resin microspheres for patients with chemotherapy-refractory liver-dominant mCRC (Cliniu200bcalTru200bialsu200b gov identifier: NCT02602327, first posted, ). A graphic overview of the study is provided in Fig., . The study was approved by the Institutional Review Board at University of California San Francisco. The study was performed in accordance with the Declaration of Helsinki. All patients signed written informed consent after being advised of risks, benefits, and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.